PDSB Live signals | Maximize Profits with Getagraph.com

SELL 102872 min ago

@ $5.26

Issued: 14 Feb 2024 @ 12:24

Return: -38.02%

Previous signal: Feb 12 - 12:29

Previous signal: Buy

Return: -3.66 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	415 019
Average Volume	922 991
Market Cap	119.57M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.35
ATR14	$0.00600 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-22	Shepard Kirk V.	Buy	200 000	Employee Stock Option (Right to Buy)
2024-01-22	Shepard Kirk V.	Buy	0
2023-12-04	Boesgaard Lars	Buy	200 000	Employee Stock Option (Right to Buy)
2023-12-04	Boesgaard Lars	Buy	0
2023-07-14	Freitag Gregory Gene	Buy	9 000	Employee Stock Option (Right to Buy)

INSIDER POWER
71.51
Last 91 transactions
Buy: 4 791 106 \| Sell: 920 084

Volume Correlation

Long: 0.01 (neutral)

Short: 0.03 (neutral)

Signal:(52.233) Neutral

PDS Biotechnology Corp Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

PDS Biotechnology Corp Correlation - Currency/Commodity

-0.25
( neutral )

0.06
( neutral )

0.00
( neutral )

0.44
( neutral )

0.38
( neutral )

PDS Biotechnology Corp Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-57 326.00 (0.00 %)
EPS:	$-1.390

Q4	2023
Revenue:	$0
Gross Profit:	$-14 405.00 (0.00 %)
EPS:	$-0.340

Q3	2023
Revenue:	$0
Gross Profit:	$-14 403.00 (0.00 %)
EPS:	$-0.350

Q2	2023
Revenue:	$0
Gross Profit:	$-74 663.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

PDS Biotechnology Corp

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.